OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

Induced pluripotent stem cells (iPSC) may provide an unlimited number of phenotypically defined, functional and expandable autologous antigen-specific T cells with the characteristics needed to combat cancer.

A 37-year old man presents with a bluish lesion in the right arm. After further assessment, a biopsy is performed. What is your diagnosis?

Patients with metastatic Merkel cell carcinoma treated with pembrolizumab (Keytruda, Merck) as a first-line therapy had durable responses in a phase II clinical trial.

More than one-third of patients with advanced melanoma were still alive 5 years after starting treatment with the anti-PD-1 immunotherapy nivolumab, according to long-term phase I data.

Researchers at the University of Colorado Cancer have created a new tool that will help oncologists match the right therapy to cancer type based on the patient's genetic data.

Neutralizing intratumoral pH may help improve responses to immunotherapy and improve outcomes with current targeted therapies, according to a study published March 15, 2016, in the journal Cancer Research.

A research team at University of California, Merced has identified a drug that could be effective in targeting melanoma cells.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.